SELLAS Life Sciences
31 hedge funds and large institutions have $6.47M invested in SELLAS Life Sciences in 2024 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 10 increasing their positions, 5 reducing their positions, and 8 closing their positions.
2,088% more call options, than puts
Call options by funds: $4.75M | Put options by funds: $217K
100% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 5
0.43% more ownership
Funds ownership: 8.41% → 8.84% (+0.43%)
4% less capital invested
Capital invested by funds: $6.76M → $6.47M (-$290K)
6% less funds holding
Funds holding: 33 → 31 (-2)
25% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$500K |
| 2 |
AFM
Anson Funds Management
Dallas,
Texas
|
+$455K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$147K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$146K |
| 5 |
State Street
Boston,
Massachusetts
|
+$60.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DC
Diametric Capital
Boston,
Massachusetts
|
-$200K |
| 2 |
Renaissance Technologies
New York
|
-$116K |
| 3 |
PCM
Prelude Capital Management
New York
|
-$72.9K |
| 4 |
Millennium Management
New York
|
-$57.9K |
| 5 |
VF
Virtu Financial
New York
|
-$43.5K |
SLS Hedge Fund Activity: Q4 2024 in Review
31 of the 7,606 institutional investors tracked by Wall St. Rank reported a position in SELLAS Life Sciences (SLS) for Q4 2024, worth a combined $6.47M — down 4.3% from $6.76M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of SLS and 6 opened new positions — a net loss of 2 holders — while 5 trimmed existing stakes and 10 added.
The largest buyer was Citadel Advisors, adding an estimated $500K. The largest seller was Diametric Capital, exiting entirely with an estimated $200K sold.
- 31 institutional investors held SELLAS Life Sciences (SLS) as of Q4 2024, down from 33 in Q3 2024.
- Funds reported $6.47M of SELLAS Life Sciences stock for Q4 2024, down 4.3% quarter-over-quarter.
- 6 funds opened new SELLAS Life Sciences positions in Q4 2024 and 8 closed out, a net change of -2 holders.
- The largest SELLAS Life Sciences buyer in Q4 2024 was Citadel Advisors, an estimated $500K added.
- The largest SELLAS Life Sciences seller in Q4 2024 was Diametric Capital, an estimated $200K sold.
Based on aggregated 13F filings for Q4 2024.